Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
381.2 INR | +2.16% | -3.47% | -17.71% |
Mar. 19 | IOL Chemicals Gets Zero Observations from Brazilian Health Regulatory Agency After Inspection of Units | MT |
Feb. 19 | IOL Chemicals Gets Nod to Export Diabetes Drug to China | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.06 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.71% | 262M | - | ||
+30.38% | 695B | C+ | ||
+26.51% | 568B | B | ||
-4.36% | 361B | C+ | ||
+19.30% | 330B | B- | ||
+3.73% | 283B | C+ | ||
+16.70% | 239B | B+ | ||
+8.78% | 204B | B- | ||
-7.93% | 198B | A+ | ||
+7.68% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IOLCP Stock
- Ratings IOL Chemicals and Pharmaceuticals Limited